Miromatrix Medical Inc. MIRO
We take great care to ensure that the data presented and summarized in this overview for Miromatrix Medical Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MIRO
Top Purchases
Top Sells
About MIRO
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
Insider Transactions at MIRO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2023
|
Peter Maag |
SELL
Sale (or disposition) back to the issuer
|
Direct |
58,368
-100.0%
|
-
|
|
Dec 13
2023
|
Lisa Wipperman Heine |
SELL
Sale (or disposition) back to the issuer
|
Direct |
67,413
-100.0%
|
-
|
|
Dec 13
2023
|
James Michael Douglas CHIEF FINANCIAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-100.0%
|
-
|
|
Dec 13
2023
|
William P. Burke Mr. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
67,413
-100.0%
|
-
|
|
Dec 13
2023
|
Paul Buckman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
54,201
-100.0%
|
-
|
|
Dec 13
2023
|
John L Erb |
SELL
Sale (or disposition) back to the issuer
|
Direct |
54,201
-100.0%
|
-
|
|
Dec 13
2023
|
Jeffrey James Ross CHIEF EXECUTIVE OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
87,500
-100.0%
|
-
|
|
Dec 12
2023
|
Peter Maag |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
62,092
-51.55%
|
-
|
|
Dec 12
2023
|
Lisa Wipperman Heine |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
66,943
-49.83%
|
-
|
|
Dec 12
2023
|
James Michael Douglas CHIEF FINANCIAL OFFICER |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
31,250
-60.98%
|
-
|
|
Dec 12
2023
|
William P. Burke Mr. |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
66,943
-49.83%
|
-
|
|
Dec 12
2023
|
Paul Buckman |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
52,593
-49.25%
|
-
|
|
Dec 12
2023
|
John L Erb |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
56,260
-50.93%
|
-
|
|
Dec 12
2023
|
Jeffrey James Ross CHIEF EXECUTIVE OFFICER |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
308,775
-77.92%
|
-
|
|
Jun 01
2023
|
Lisa Wipperman Heine |
BUY
Grant, award, or other acquisition
|
Direct |
54,201
+28.75%
|
-
|
|
Jun 01
2023
|
William P. Burke Mr. |
BUY
Grant, award, or other acquisition
|
Direct |
54,201
+28.75%
|
-
|
|
Jun 01
2023
|
John L Erb |
BUY
Grant, award, or other acquisition
|
Direct |
54,201
+32.92%
|
-
|
|
Jun 01
2023
|
Peter Maag |
BUY
Grant, award, or other acquisition
|
Direct |
54,201
+31.03%
|
-
|
|
Jun 01
2023
|
Paul Buckman |
BUY
Grant, award, or other acquisition
|
Indirect |
54,201
+33.67%
|
-
|
|
Mar 10
2023
|
Jeffrey James Ross CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
31,250
+7.31%
|
$31,250
$1.6 P/Share
|